Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
Sanberg, Paul R.; Shytle, Roland D.; and Silver, Archie A., "Nicotine antagonists for nicotine-responsive neuropsychiatric disorders" (2000). USF Patents. 830.
University of South Florida